002644 佛慈制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.1093.3983.8796.5195.835
总资产报酬率 ROA (%)1.5252.4042.6174.3833.936
投入资产回报率 ROIC (%)2.0253.2213.5785.9915.381

边际利润分析
销售毛利率 (%)32.91930.57631.06229.28027.292
营业利润率 (%)6.9847.1877.16013.73213.742
息税前利润/营业总收入 (%)6.3576.5286.59111.80912.474
净利润/营业总收入 (%)5.9526.2915.85710.49011.438

收益指标分析
经营活动净收益/利润总额(%)141.317110.620102.84470.52958.429
价值变动净收益/利润总额(%)-13.281-10.462-5.501-0.992-0.766
营业外收支净额/利润总额(%)-3.092-1.889-2.000-9.509-1.397

偿债能力分析
流动比率 (X)3.1043.2182.6492.4032.760
速动比率 (X)2.3162.3221.8581.7342.070
资产负债率 (%)26.86326.51330.04933.19530.806
带息债务/全部投入资本 (%)-8.441-11.232-8.628-8.598-12.442
股东权益/带息债务 (%)-1,131.803-859.139-1,078.540-1,063.428-742.830
股东权益/负债合计 (%)268.707273.346229.753198.687222.825
利息保障倍数 (X)-15.215-12.421-15.412-16.152-11.559

营运能力分析
应收账款周转天数 (天)139.223109.100103.742110.31395.917
存货周转天数 (天)217.948187.723164.541151.898156.584